METAL MEDIATED SCHIFF BASES FOR MEDICINAL AGENT SYNTHESIS

用于药物合成的金属介导席夫碱

• 批准号: 3734652
• 负责人: XIU R BU
• 金额: --
• 依托单位: CLARK ATLANTA UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3734652
• 关键词: Schiff bases; antineoplastics; biological products; catalyst; chemical binding; drug design /synthesis /production; metal complex; platinum; stereoisomer; tin; titanium

Our research is aimed to develop low-cost and highly efficient asymmetric catalysts for practical uses in pharmaceutical syntheses, e.g., syntheses of intermediates of biologically active natural products and ethical drug components. Subsequently, we will apply these asymmetric catalysts to organic transformations important to the pharmaceutical syntheses. This project will clearly address important issues towards development of chiral medicines. Other components of our research include (1) development of bioactive agents based on transition metal complexes, g.g., titanium, platinum and tin complexes. The interaction of these complexes with the biomolecules will be investigated to gain understanding of structural and binding nature of anti-tumor drugs in biosystem; (2) development of new ligands and host molecules which will selectively bind heavy metals and toxic (guest) molecules for health related environmental evaluation and remediation.

我们的研究旨在开发低成本、高效率的不对称 用于药物合成的实际使用的催化剂，例如合成 生物活性天然产物和医用药物的中间体 组件。随后，我们将把这些不对称催化剂应用于 对药物合成很重要的有机转化。这 项目将明确解决发展的重要问题 手性药物。我们研究的其他部分包括(1) 基于过渡金属络合物的生物活性物质的研究进展 G.G.钛、铂和锡的络合物。它们之间的相互作用 与生物分子的络合物将被研究以获得 对我国抗肿瘤药物结构和结合性的认识 生物系统；(2)开发新的配体和宿主分子，将 选择性地结合重金属和有毒(客体)分子以利于健康 相关的环境评估和修复。